Valuation: Zentalis Pharmaceuticals, Inc.

Market Cap 256M 224M 212M 193M 361M 24.5B 364M 2.54B 982M 12.52B 960M 939M 40.23B P/E 2026 *
-1.25x
P/E 2027 * -1.41x
Enterprise Value 51.06M 44.81M 42.32M 38.57M 72.2M 4.89B 72.71M 506M 196M 2.5B 192M 188M 8.04B EV / Sales 2026 *
-
EV / Sales 2027 * 7.8x
Free-Float
78.12%
Yield 2026 *
-
Yield 2027 * -
1 day-1.82%
1 week-13.18%
Current month-28.19%
1 month-30.59%
3 months-33.17%
6 months+1.12%
Current year+100.00%
1 week 2.65
Extreme 2.65
3.15
1 month 2.65
Extreme 2.65
4.19
Current year 1.32
Extreme 1.32
6.95
1 year 1.21
Extreme 1.212
6.95
3 years 1.01
Extreme 1.01
21.34
5 years 1.01
Extreme 1.01
87.19
10 years 1.01
Extreme 1.01
87.19
Manager TitleAgeSince
Chief Executive Officer 62 13/11/2024
Director of Finance/CFO - 13/11/2024
Chief Tech/Sci/R&D Officer 51 13/11/2024
Director TitleAgeSince
Chairman 61 16/05/2022
Director/Board Member 44 09/02/2021
Director/Board Member 59 12/09/2022
Date Insider Type Main position Quantity % Market Cap. Importance
14/08/26 Buy 4,335,000 4.5791%
26/05/26 Free

Director

114,200 0.1604%
06/02/26 Sell

Chief Technology Officer

3,297 0.0046%
Change 5-day change 1-year change 3-year change Capi.($)
-1.82%-13.18%+74.19%-86.82% 256M
-3.30%+1.50%+57.79%+99.14% 72.26B
+1.25%-3.01%+37.83%+87.66% 60.24B
+2.12%+5.26%+35.69%+23.40% 27.73B
-3.06%-1.81%-14.01%+357.24% 25.74B
-0.75%+2.56%+0.45%-3.28% 24.75B
+0.40%+0.75%+23.72%-11.33% 20.74B
-1.70%-2.12%+150.24%+326.97% 15.06B
+0.36%-0.34%+48.98%+167.40% 14.42B
+0.21%+1.17%-3.95%+512.06% 14.23B
Average -0.63%-0.92%+41.09%+147.24% 27.54B
Weighted average by Cap. -0.77%+0.30%+38.19%+132.80%

Financials

2026 *2027 *
Net sales - 14.89M 13.07M 12.34M 11.25M 21.05M 1.43B 21.2M 148M 57.19M 729M 55.9M 54.69M 2.34B
Net income -164M -144M -136M -124M -232M -15.74B -234M -1.63B -631M -8.04B -617M -603M -25.84B -171M -150M -141M -129M -241M -16.36B -243M -1.69B -656M -8.36B -641M -627M -26.86B
Net Debt -205M -179M -170M -154M -289M -19.6B -291M -2.03B -786M -10.02B -768M -751M -32.19B -139M -122M -116M -105M -197M -13.37B -199M -1.38B -536M -6.83B -524M -512M -21.95B
Logo Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is engaged in developing azenosertib (ZN-c3), a potentially first-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. The inhibition of WEE1, a DNA damage response kinase, drives cancer cells into mitosis without being able to repair damaged DNA, resulting in cell death and thereby preventing tumor growth and potentially causing tumor regression. WEE1 acts as a regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent replication of cells with damaged DNA. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types.
Employees
106
Date Price Change Volume
25/09/26 $2.700 -1.82% 1,067,407
24/09/26 $2.750 -4.18% 1,174,546
23/09/26 $2.870 -6.82% 1,453,568
22/09/26 $3.080 +1.65% 956,313
21/09/26 $3.030 -2.57% 675,636
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
2.700USD
Average target price
6.889USD
Spread / Average Target
+155.14%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ZNTL Stock